- recruitingPHASE2
Dapagliflozin and Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV)
This study looks at how two medicines, Bosentan and dapagliflozin, might help people with a condition called Large Vessel Vasculitis (LVV). LVV damages blood vessels, increasing risks like heart attacks. We want to see if these medicines can improve blood vessel health.
United Kingdom - not yet recruitingNA
Long-Axial Field of View (LAFOV) [18F]FDG PET/CT Imaging in Large Vessel Vasculitis (LVV): Protocol Optimisation Study.
This study aims to improve how we diagnose and monitor a condition called Large Vessel Vasculitis (LVV) using a new type of body scan. The goal is to make these scans clearer, faster, and potentially lead to better, more personalised treatment plans for patients with LVV.
United Kingdom - not yet recruiting
Mapping B-cell Biology Across the Cardiovascular Territories of Giant Cell Arteritis: Towards a New Therapeutic Approach (RituxiMAP GCA)
This study looks at a serious blood vessel condition called Giant Cell Arteritis (GCA). We're using a special scan to see tiny immune cells, called B cells, in the blood vessels. We want to find out if targeting B cells with new treatments could help people with GCA, reducing the need for strong steroid medications.
United Kingdom - recruiting
AYLo - AutoimmunitY and Loss of y
This study looks at how changes in your `Y` chromosome, which only men have, might be linked to certain long-term conditions like arthritis and similar diseases. Researchers want to understand if these changes affect how your immune system works and the progression of these conditions.
Germany - ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to investigate the efficacy and safety of secukinumab 300 mg and 150 mg administered subcutaneously versus placebo, in combination with a glucocorticoid taper regimen, in patients with giant cell arteritis (GCA) (GCAptAIN)
This study is testing a new medicine, secukinumab, for giant cell arteritis (GCA). It compares different doses of secukinumab with a dummy medicine (placebo), alongside a common steroid treatment. The aim is to see if secukinumab can help people with GCA stay well for longer.
Estonia · Sweden · Hungary